Liraglutide


Daily GLP-1 receptor agonist

A daily-dosing GLP-1 analog FDA-approved as Victoza (T2DM, 2010) and Saxenda (obesity, 2014); the predecessor of semaglutide.

Abstract

Liraglutide (Victoza, Saxenda; CAS 204656-20-2; molecular weight 3751.20) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA for T2DM (2010) and obesity (2014). The compound features a 16-carbon fatty acid (palmitoyl) chain attached to lysine 26 via a glutamic acid spacer, enabling reversible albumin binding for extended half-life of approximately 13 hours, supporting once-daily subcutaneous dosing. Liraglutide was the first GLP-1 agonist approved for chronic weight management.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph